WASHINGTON, D.C.—Intratumoral C-reactive protein (CRP) may be a robust biomarker of prognosis in patients with local renal cell carcinoma (RCC), investigators reported at the American Urological Association 2011 annual meeting.
Viraj Master, MD, PhD, Assistant Professor of Medicine at Emory University School of Medicine in Atlanta, and colleagues followed 95 patients with fully resected clinically localized clear cell RCC for up to 46 months post-operatively, with a mean follow-up of 29.8 months.
During follow-up, 12 patients (12.6%) died. Using intratumoral CRP staining, investigators graded tumors as low, intermediate, and high risk in 49.5%, 25.3%, and 25.3% of patients, respectively. Mean overall survival for low-, intermediate-, and high-risk groups was 44.2 months, 40.5 months, and 31.6 months, respectively.
Continue Reading
Patients in the high-risk group had a 12-fold increased risk of overall mortality compared with patients in the low-risk group.
